Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life SettingMariele Gatto, Roberto Gerli, Francesca Saccon et al.|Arthritis & Rheumatology|2020Cited by 113
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndromeC. Belizna, Laurent Loufrani, Howard Amital et al.|Autoimmunity Reviews|2018Cited by 76